The elevated levels of Olfr734 in obesity prompted us to hypothesize that the targeted inhibition of Olfr734 in the liver could be a promising strategy for improving MASLD treatment. This evidence concerns the gene OR4M1 and obesity due to melanocortin 4 receptor deficiency.